Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.11), $0.02 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $99.31 million versus the consensus estimate of $87.12 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.